- Home
- CVKD vs RLYB Comparison
CVKD vs RLYB Comparison
Compare CVKD & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- RLYB
- Stock Information
- Founded
- CVKD 2022
- RLYB 2018
- Country
- CVKD United States
- RLYB United States
- Employees
- CVKD N/A
- RLYB N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- RLYB Health Care
- Exchange
- CVKD Nasdaq
- RLYB Nasdaq
- Market Cap
- CVKD 27.0M
- RLYB 24.1M
- IPO Year
- CVKD 2023
- RLYB 2021
- Fundamental
- Price
- CVKD $14.13
- RLYB $0.61
- Analyst Decision
- CVKD Strong Buy
- RLYB Hold
- Analyst Count
- CVKD 1
- RLYB 2
- Target Price
- CVKD $32.00
- RLYB N/A
- AVG Volume (30 Days)
- CVKD 25.8K
- RLYB 290.8K
- Earning Date
- CVKD 11-07-2025
- RLYB 11-07-2025
- Dividend Yield
- CVKD N/A
- RLYB N/A
- EPS Growth
- CVKD N/A
- RLYB N/A
- EPS
- CVKD N/A
- RLYB N/A
- Revenue
- CVKD N/A
- RLYB $761,000.00
- Revenue This Year
- CVKD N/A
- RLYB N/A
- Revenue Next Year
- CVKD N/A
- RLYB N/A
- P/E Ratio
- CVKD N/A
- RLYB N/A
- Revenue Growth
- CVKD N/A
- RLYB 154.51
- 52 Week Low
- CVKD $8.74
- RLYB $0.22
- 52 Week High
- CVKD $22.90
- RLYB $1.24
- Technical
- Relative Strength Index (RSI)
- CVKD 54.38
- RLYB 61.83
- Support Level
- CVKD $12.11
- RLYB $0.54
- Resistance Level
- CVKD $14.35
- RLYB $0.57
- Average True Range (ATR)
- CVKD 0.66
- RLYB 0.04
- MACD
- CVKD -0.08
- RLYB 0.01
- Stochastic Oscillator
- CVKD 76.99
- RLYB 93.92
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.